The oral GLP-1 weight loss pill that could change everything
Peter Paumgardhen | Last update: 30th May 2025
Imagine taking a simple pill instead of sticking a needle in your leg once a week. For many SlimrChat users, that might sound like a dream. Novo Nordisk’s latest announcement could make it real—and soon. The Danish pharma giant has submitted its application to the FDA for the first-ever oral version of a GLP-1 weight loss drug. If approved, it’s not just a new pill — it’s a whole new way of losing weight.
A once-a-day pill instead of weekly jabs?
Novo Nordisk, the makers of popular weight loss drugs like Wegovy and Ozempic, is shaking things up again. This time, they’ve gone needle-free. Their new product, an oral GLP-1 weight loss pill, is a once-daily version of Wegovy containing 25mg of semaglutide, the same active ingredient found in the injectable version (Source).
The FDA has already accepted their New Drug Application. That doesn’t mean it’s approved yet, but it’s a big first step. If greenlit, this would be the first GLP-1 weight loss treatment available in pill form.
Why does this matter? Because let’s face it — not everyone is comfortable injecting themselves. For many, the idea of a daily pill sounds easier, more discreet, and a lot less intimidating.
Could a pill actually work as well as the jab?
That’s the million-pound question. Novo Nordisk says the pill performed well in late-stage trials, involving over 300 adults with obesity and related conditions. Users taking the 25mg dose showed significant weight loss, although final data haven’t been made public yet.
Some early results even hint that the pill may be just as effective (or possibly more) than current injectables. Plus, it could appeal to those who’ve avoided weight loss drugs altogether due to a fear of needles.
And it doesn’t stop there. Novo Nordisk is also working on another oral treatment called amycretin, and early data suggests it might outperform Wegovy entirely. Meanwhile, Eli Lilly, the maker of Mounjaro, is making its own big oral move with Orforglipron, a once-daily weight loss pill many are calling a game changer. Read more here.
Billion-dollar bets on a pill-shaped future
Novo Nordisk isn’t just playing around. They’ve just struck a $2.2 billion deal with a biotech firm called Septerna to develop even more oral treatments for obesity. This includes not just GLP-1s, but other next-gen targets like GIP and glucagon.
The message is clear: oral treatments are the future, and Novo Nordisk wants to lead the charge.
What does this mean for the SlimrChat community?
If you’re part of our SlimrChat forums and just learning about your options, this news matters. Not everyone can easily access injectables, and some members have told us that remembering a weekly jab or dealing with side effects felt daunting.
As one member shared in our chats:
“It’s not just the needle. It’s the build-up before every injection. If there was a pill, I’d jump on it in a heartbeat.”
This oral GLP-1 weight loss pill could open the door for many people who are still deciding. It might also mean fewer side effects since oral medications sometimes absorb differently in the body, though that remains to be seen.
For now, we’re watching closely. And you can bet SlimrChat will be one of the first places to break it down when the decision comes in.
Always check with your healthcare provider
While we’re excited, we want to be clear: this isn’t medical advice. Always consult your doctor or healthcare provider when considering weight loss treatments. Your journey is your own — and we’re here to support it.